This study aimed to evaluate the efficacy of transurethral thulium laser en bloc resection of the bladder tumor (TmLRBT) in patients with non-muscle invasive bladder cancer (NMIBC) and to investigate whether a second resection can be avoided.
From June 2012 to June 2018, 251 newly diagnosed patients with NMIBC were enrolled in this retrospective study; all patients received regular administration of pirarubicin after the initial resection. A second transurethral resection (TUR) was performed in patients within 2-6 weeks after the initial TmLRBT in group 1. Patients in group 2 only underwent cystoscopy at 3 months.
Second surgery results indicate that recurrence was detected histopathologically in 6/108 and 11/143 patients in group 1 and 2, respectively (P = 0.52); Progression was observed in 2 patients in each group (P = 0.34). The mean follow-up duration was 40.1 months, with no significant difference between the groups (P = 0.32). Recurrence was observed in 23 (21.3%) and 39 (27.3%) patients in groups 1 and 2 during the follow-up, respectively (P = 0.34); disease progression occurred in 4 (3.8%) patients in group 1 compared with 7 (4.0%) in group 2 (P = 0.20).
Complete removal of tumors can be achieved by TmLRBT. This technique may decrease the number of second TURs.
BMC urology. 2020 Mar 18*** epublish ***
Wenhao Zhou, Wei Wang, Wenbo Wu, Tingmang Yan, Guofang Du, Haitao Liu
Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100, Haining Road, Shanghai, 200080, China., Weifang Second People's Hospital, No.7 YuanXiao Street, Kuiwen District, WeiFang City, 261041, ShanDong Province, China., Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100, Haining Road, Shanghai, 200080, China. .